Back to News
Market Impact: 0.2
OSE Immunotherapeutics Reports First Patient Dosed In Phase 2 RENGEVITY-201 Trial Of Pegrizeprument
Source: Nasdaq
Healthcare & Biotech
OSE Immunotherapeutics' licensee Veloxis Pharmaceuticals, an Asahi Kasei company, dosed the first patient in the Phase 2 RENGEVITY-201 trial of pegrizeprument. The study evaluates the drug's potential to prevent organ rejection in kidney transplant recipients, marking a clinical-development milestone with early-stage validation potential.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
OSE0.55
More News
- Biotech stocks are surging. How investors can play the new drug innovation boom
- IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
- J&J prostate cancer drug shows promising tumor responses in early trial
- Pfizer reports phase 2 data for 25-valent pneumococcal vaccine
- Fact vs. fiction: Doctors share whether peptides are safe and effective
- Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Capital IQ Alternatives for Research and Deal Work
- Research Workflows, Report Format Selection, and Interactive Synthesis